Venetoclax

TRANSCEND CLL 004 study data showed Breyanzi with Imbruvica achieved 86% response rate and 45% complete remission in relapsed/refractory CLL/SLL patients. Breyanzi, first CAR T therapy for CLL, targets unmet need in patients failing BTK and BCL2 inhibitors. Breyanzi sales projected to reach $2.6 billion by 2030.

ASH meeting featured studies on BTK inhibitors in CLL, including Jaypirca's Phase 3 trial showing improved progression-free survival and fewer side effects. AstraZeneca's Calquence combined with Venclexta reduced progression risk by 35%. Pfizer's Oxbryta withdrawal due to safety concerns raised questions on sickle cell drug approvals. Bristol Myers Squibb presented positive survival data for its GPRC5D-targeted CAR-T therapy, arlo-cel, in multiple myeloma.

Genetic tests identify patients with multiple myeloma likely to respond to Venclexta, with a six-gene pattern predicting response. Venclexta, approved in 2018, inhibits BCL-2 to restore natural cell death. Combining Venclexta with CDK7 inhibitors may enhance patient response, with further studies planned.

Genetic tests can predict which multiple myeloma patients will respond to Venclexta, with a six-gene pattern indicating likelihood of response. Combining Venclexta with CDK7 inhibitors may improve outcomes, especially for patients less responsive to Venclexta alone.

AbbVie (NYSE: ABBV), Realty Income (NYSE: O), and Verizon Communications (NYSE: VZ) are recommended for long-term passive income due to their consistent dividend growth and strong financial positions.

FDA approves Syndax Pharma's Revuforj, an oral menin inhibitor, for relapsed or refractory acute leukaemia with KMT2A gene translocations, marking the first FDA-backed treatment for this type of blood cancer. This follows a disappointing phase 1/2 trial readout for Revuforj in mutant NPM1 acute myeloid leukaemia, causing a drop in Syndax's shares.

Nicole Lamanna discussed the progression in CLL patients with covalent BTK inhibitors and venetoclax, emphasizing the need for new treatments. She highlighted clinical trials and CAR T-cell therapy options, including the TRANSCEND CLL 004 trial with lisocabtagene ciloleucel, and the CaDAnCE-101 trial with BGB-16673. Lamanna also presented the EPCOR trial with epcoritamab-bysp, suggesting bispecific antibodies as potential next steps for CLL treatment.

A fixed-duration venetoclax-based regimen for first-line chronic lymphocytic leukemia (CLL) treatment results in lower long-term health care costs compared to continuous Bruton tyrosine kinase inhibitor (BTKi) treatment, with an approximate $8000 decrease in costs 6 months post-fixed-duration period. The study, based on Medicare claims data from 2016 to 2021, found similar all-cause costs during the first 12 months for both treatments but a significant drop in costs for the venetoclax-based regimen in the subsequent 6 months, largely due to the absence of prescription drug costs.

Genentech presents key studies on Polivy, Lunsumio, Columvi, Venclexta, Hemlibra, and PiaSky at medical conferences, highlighting efficacy and safety profiles of these medicines in treating various blood cancers and hemophilia A.

Eli Lilly missed Q3 estimates, lowered guidance; Merck beat estimates, initiated phase III study; Pfizer beat estimates, raised 2024 guidance; AbbVie beat estimates, acquired Aliada, collaborated with EvolveImmune; Novartis beat estimates, raised 2024 expectations, FDA approved Scemblix expansion.